Boston Scientific (BSX)

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE: BSX) for violations of the securities laws.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026. Boston Scientific describes itself as a “a global company that develops, manufactures, and markets medical devices used across various specialties.”

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. Boston Scientific is a global company that develops, manufactures, and markets medical devices used across various specialties.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

A group of emerging biotech and healthcare companies is gaining attention as they advance novel technologies across oncology, regenerative medicine, infection prevention, and precision radiotherapy—sectors that remain top priorities for global healthcare systems and investors alike. From late-stage cancer immunotherapy programs to next-generation hygiene platforms and regenerative biologics, these five companies represent distinct but complementary approaches to addressing high-value medical needs.

BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

CS Diagnostics Corp. (OTCQB: CSDX), a medical technology innovator , continues to advance cancer treatment technology with CS Protect-Hydrogel , a groundbreaking tissue spacer that enhances radiation therapy by protecting healthy tissue. Alongside this milestone, the company has also launched MEDUSA , a next-generation smart disinfectant designed to revolutionize hygiene standards across industries.

For investors seeking high-potential stocks priced under $2, several companies stand out due to their innovative offerings, upcoming developments, or strategic positioning in the market. Here’s a look at five noteworthy companies to watch in addition to Sana Biotechnology (NASDAQ: SANA) and CS Diagnostics Corp. (OTCQB: CSDX) in January 2025.

The healthcare and technology sectors are experiencing unprecedented growth as companies push the boundaries of innovation to address critical global challenges. From revolutionary treatments for cardiovascular disease to AI-powered tools and cutting-edge medical devices, these advancements are reshaping industries and creating significant opportunities for investors. Market leaders and emerging innovators alike are driving transformative change, paving the way for a healthier, more connected future.

Today's market update highlights exciting developments across key companies demonstrating innovation, growth potential, and strategic progress. From dividend shares and stock splits to groundbreaking medical advancements, these companies offer compelling opportunities for investors to watch.

Boston Scientific Co (NYSE: BSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.

Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases

CS Diagnostics Group (OTC: FZRO) signed a landmark agreement to sell and transfer tangible and intangible assets, including patents, for the CS Protect-Hydrogel to CS Diagnostics Corp. The hydrogel-based tissue spacer, designed for radiation therapy, increases the distance between healthy tissue and cancer cells, protecting healthy tissues from high radiation doses.

Boston Scientific Corporation (NYSE: BSX), a global leader in medical device technology, announced to acquire Silk Road Medical, Inc. (NASDAQ: SILK) in a definitive agreement valued at approximately $1.16 billion in cash. This strategic acquisition is set to enhance Boston Scientific's vascular intervention portfolio, particularly in stroke prevention and treatment.

Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash